Results 81 to 90 of about 878 (159)

Live attenuated SARS-CoV-2 vaccine OTS-228 demonstrates efficacy, safety, and stability in preclinical model

npj Vaccines
Live attenuated vaccines (LAV) have the potential to meet all the criteria for an efficacious vaccine. In addition to providing protection against the target disease, they offer the potential to prevent transmission, provide cross-protection by ...
Tobias Britzke, Nico Joël Halwe, Lorenz Ulrich, Angele Breithaupt, G. Tuba Barut, Claudia Wylezich, Nadine Ebert, Bettina Salome Trüeb, Volker Thiel, Donata Hoffmann, Martin Beer, Jacob Schön   +11 more
doaj   +1 more source

Study of practical biorisk management in microbiological containment laboratories

Uirusu
Biosafety Level 4 facilities have been established in our country to promote research and development and national capacity of diagnostic test systems for infectious diseases, including highly pathogenic viruses. In particular, the operation of a suit-type laboratory requiring positive pressure protective suits is a first for our country, and it is ...
Yohei, Kurosaki, Ken-Ichi, Hanaki, Shuetsu, Fukushi, Masayuki, Shimojima, Yasuhiro, Kawai, Asuka, Nanbo, Katuaki, Shinohara, Shintaro, Shichinohe   +7 more
openaire   +2 more sources

Genetic variation associated with increased lambda-cyhalothrin resistance in Spodoptera frugiperda (Lepidoptera: Noctuidae) in West Africa

Scientific Reports
The fall armyworm Spodoptera frugiperda (J.E. Smith) is a new serious destructive and widespread pest of corn which recently invaded subtropical regions worldwide.
Eric Tossou, Ghislain T. Tepa-Yotto, Georg Goergen, Genevieve M. Tchigossou, Magellan Tchouakui, Daniel Nguiffo Nguete, Laouali Amadou, Moussa Noussourou, Aimé H. Bokonon-Ganta, Charles Wondji, Manuele Tamò, Rousseau Djouaka   +11 more
doaj   +1 more source

Editorial: Biorisk management, laboratory acquired infections and clinical containment

Frontiers in Public Health, 2023
Kashif Ali, Furqan Kabir, Esmeralda Meyer   +2 more
doaj   +1 more source

Infectious adverse events in patients treated with biotherapies in a tropical Amazonian context, French Guiana. [PDF]

BMC Infect Dis
Pasquer R, Pierre-Louis D, Aissaoui H, Louvel D, Aboikoni A, Gbaguidi T, Sidibe M, Belgrine M, Montagnac C, Deschamps N, Grotta G, Blaizot R.   +11 more
europepmc   +1 more source

Navigating change: the ongoing efforts to contain poliovirus in the United States. [PDF]

Front Bioeng Biotechnol
Ottendorfer C, Haynes Smith L, Jorgensen S.   +2 more
europepmc   +1 more source

Implementation of Poliovirus Containment in Poliovirus Designated Facilities-United States, 2017-2024. [PDF]

Pathogens
Ottendorfer C, Vander Kelen P, Sanders CA, Watson E, Suppiah S, Hoffman W, Sinclair C, Marfo A, Haynes Smith L.   +8 more
europepmc   +1 more source

Landscape of Dual-Use Research Governance in Malaysia. [PDF]

Appl Biosaf
Vengadesen S, Chai LC, Chau DM.
europepmc   +1 more source

Implementation of a Biorisk Management System in Armenia for ISO 35001:2019 Certification. [PDF]

Appl Biosaf
Danelyan H, Tumanyan P.
europepmc   +1 more source

Improving governance in the age of synthetic biology, artificial intelligence, and diverging threats. [PDF]

Front Bioeng Biotechnol
Sabra DM, Frieß JL, Giese B, Jeremias G.   +3 more
europepmc   +1 more source